Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-13

Study Completion Date

2025-07-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Using sensitive markers (such as thyroglobulin, etc) to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer

NCT00004917

Anemia Head and Neck Cancer

COMPLETED PHASE3

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

NCT06957938

Laryngeal Carcinoma Hypopharyngeal Carcinoma

NOT_YET_RECRUITING PHASE3

A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx

NCT02055989

Locally Advanced Larynx, Hypopharyngeal Squamous Cell Cancers Locally Advanced Thyroid Cancers

COMPLETED PHASE1/PHASE2

Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer

NCT00004089

Head and Neck Cancer

COMPLETED PHASE2

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

NCT04589624

Thyroid Gland Carcinoma

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Using biochemical markers (such as thyroglobulin), functional markers (such as change of tumor-background ratio on bone scan), etc to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thyroid Neoplasm Follicular Bone Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Sr-89 treatment

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sr-89 treated group

Sr-89 treatment

Group Type EXPERIMENTAL

Sr-89

Intervention Type DRUG

1. strontium-89 chloride treatment
2. periodical evaluation and follow-up

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sr-89

1. strontium-89 chloride treatment
2. periodical evaluation and follow-up

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

strontium-89 chloride

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of differentiated thyroid cancer
* Positive uptake by bone metastases on bone scan
* Planing to have Sr-89 treatment

Exclusion Criteria

* Having received treatment for bone metastases within one month of the study (such as radiotherapy, surgery, targeted therapy, chemotherapy, etc., among which denosumab and bisphosphate were allowed as basic treatment)
* Having received radioactive iodine therapy within half a year before the study
* There are bone related events, such as fracture, spinal cord compression, etc.

Eligible Sex

ALL

Accepts Healthy Volunteers

No